.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Alzheimer’s disease presents a significant challenge for modern medicine, creating an urgent need for neuroregenerative treatments. Recent research indicates that NeuroD1 gene therapy effectively repairs functional brain damage in non-human primate models. This innovative approach targets hippocampal degeneration, which typically leads to severe memory loss.
Scientists utilized an adeno-associated virus (AAV) vector to deliver the NeuroD1 gene into the hippocampus. Consequently, the therapy prevented neuronal damage and significantly reduced neuroinflammation. Moreover, researchers observed a restoration of the blood-brain barrier and vascular integrity. These improvements coincided with enhanced spatial working memory and stabilized hippocampal glucose metabolism.
The study employed advanced imaging, including MRI and FDG PET scans, to monitor brain changes. Results showed that the treatment inhibited hippocampal atrophy. Furthermore, transcriptome analysis confirmed the upregulation of neuronal function and synaptic transmission pathways. Because the primate model closely reflects human pathology, these findings offer substantial hope for future clinical applications.
It acts as a master transcription factor that facilitates the conversion of glial cells into functional neurons, thereby repairing damaged brain circuits.
The therapy restores CSF AD biomarker levels to more normal ranges, suggesting a systemic improvement in brain health and pathology.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Jiang Z et al. A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model. Adv Sci (Weinh). 2026 Mar 10. doi: 10.1002/advs.202520239. PMID: 41806359.
Ge L-J, et al. In vivo Neuroregeneration to Treat Ischemic Stroke Through NeuroD1 AAV-Based Gene Therapy in Adult Non-human Primates. Front Cell Dev Biol. 2020;8:590008.
Chen YC, et al. A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair after Ischemic Injury through In Vivo Astrocyte-to-Neuron Conversion. Mol Ther. 2020;28(1):217-234.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research demonstrates that NeuroD1 AAV-based gene therapy repairs brain function, inhibits atrophy, and improves memory in Alzheimer's primate models....
7 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
